Prolyl hydroxylase inhibitors
AssigneeAerpio Therapeutics Inc.
InventorsJoseph H. Gardner, Robert Shalwitz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.
Claims20
A method for treating an infection in a human or mammal caused by a microorganism, comprising administering to a human or mammal one or more compounds of the formula:
- wherein Z is phenyl substituted with from 1 to 5 halogens chosen from fluorine and chlorine;
- wherein R4 is C1-C4 linear alkyl or C3-C4 branched alkyl;
- or a pharmaceutically acceptable salt thereof.
A method for treating anemia in a subject, comprising administering to a subject an effective amount of a compound having the formula:
- wherein Z is phenyl substituted with from 1 to 5 halogens chosen from fluorine and chlorine;
- wherein R4 is C1-C4 linear alkyl or C3-C4 branched alkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.